Latest Breaking News On - Bellus health inc - Page 1 : vimarsana.com

BELLUS Health (TSE:BLU) Shares Pass Below 50 Day Moving Average of $19 48

BELLUS Health Inc. (TSE:BLU – Get Free Report) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of C$19.48 and traded as low as C$19.24. BELLUS Health shares last traded at C$19.48, with a volume of 28,666 shares changing hands. BELLUS Health Price Performance The stock’s […]

Health incHealth dailyBellus health incHealth price performanceGet free report

PJT Partners Dealmaker Davidson to Join Leerink as Co-President

PJT Partners Dealmaker Davidson to Join Leerink as Co-President
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Tom davidsonCredit suisseHorizon therapeutics plcMerrill lynchAmgen incPartners incBellus health incBlackstone incLeerink partners

BELLUS Health (TSE:BLU) Stock Price Down 0 1%

BELLUS Health Inc. (TSE:BLU – Get Free Report)’s stock price traded down 0.1% during mid-day trading on Monday . The stock traded as low as C$19.24 and last traded at C$19.48. 28,666 shares changed hands during trading, a decline of 52% from the average session volume of 59,471 shares. The stock had previously closed at […]

Bellus health incHealth incHealth price performanceHealth dailyGet free reportBellus healthTse blu

GSK Expands Respiratory Pipeline With Aiolos Bio Buy -- 2nd Update

By Christian Moess Laursen GSK is buying biopharmaceutical company Aiolos Bio for up to $1.4 billion in a deal that expands its respiratory pipeline and follows a string of pharmaceutical.

San franciscoUnited statesUnited kingdomCity ofTony woodKaruna therapeuticsnoChristian moess laursenAiolos bioBellus health incLondon based aiolos bioScientific officer tony woodWall street journalBellus healthDow jones

Adcom s focus on chronic cough drug could shape future of the space

The U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee has a lot to discuss Nov. 17, but only one voting question: Does the evidence demonstrate that Merck & Co. Inc.’s gefapixant provides a clinically meaningful benefit to adults with refractory or unexplained chronic cough?

Merck coAllergy drugs advisory committeeChronic coughMerck amp co incAdvisory committeeShionogi incBellus health inc